Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York City, February 26-27, 2024
The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.
- The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.
- Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r).
- If you are attending BIO CEO & Investors, we would like to talk to you about investing in Pacylex and zelenirstat, a first-in-class oral cancer drug in Phase 2.
- Zelenirstat has a great safety profile and evidence of benefit in refractory patients with solid and liquid tumors.